Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology)

重组人源化抗CD52单克隆抗体（兰州生物制品研究所/上海泰因生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCAMPATH-1 antigen inhibitors
TargetsCAMPATH-1 antigen
Therapy Area/IndicationsLymphoma, T-CellLymphoma, Non-HodgkinLymphoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLanzhou Institute Of Biological Products Co LtdShanghai Taiyin Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Taiyin Biotechnology Co LtdLanzhou Institute Of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinLymphomaLeukemia, Prolymphocytic, T-Cell +[6] 
Inactive IndicationsLymphoma, T-Cell

Other Information

ATC CodeN/A
Related LinksN/A